268 related articles for article (PubMed ID: 32515349)
21. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
[TBL] [Abstract][Full Text] [Related]
22. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.
Collins MT
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703179
[TBL] [Abstract][Full Text] [Related]
23. ACVR1 Function in Health and Disease.
Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
[No Abstract] [Full Text] [Related]
24. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
[TBL] [Abstract][Full Text] [Related]
25. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.
Cappato S; Giacopelli F; Ravazzolo R; Bocciardi R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587443
[TBL] [Abstract][Full Text] [Related]
26. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.
Shen Q; Little SC; Xu M; Haupt J; Ast C; Katagiri T; Mundlos S; Seemann P; Kaplan FS; Mullins MC; Shore EM
J Clin Invest; 2009 Nov; 119(11):3462-72. PubMed ID: 19855136
[TBL] [Abstract][Full Text] [Related]
27. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
[TBL] [Abstract][Full Text] [Related]
28. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.
Allen RS; Tajer B; Shore EM; Mullins MC
Elife; 2020 Sep; 9():. PubMed ID: 32897189
[TBL] [Abstract][Full Text] [Related]
29. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
[TBL] [Abstract][Full Text] [Related]
30. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701
[TBL] [Abstract][Full Text] [Related]
31. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
[TBL] [Abstract][Full Text] [Related]
32. Variable signaling activity by FOP ACVR1 mutations.
Haupt J; Xu M; Shore EM
Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
[TBL] [Abstract][Full Text] [Related]
33. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
[TBL] [Abstract][Full Text] [Related]
34. AAV-Mediated Targeting of the Activin A-ACVR1
Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
[TBL] [Abstract][Full Text] [Related]
35. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
[TBL] [Abstract][Full Text] [Related]
36. Activin A does not drive post-traumatic heterotopic ossification.
Hwang C; Pagani CA; Das N; Marini S; Huber AK; Xie L; Jimenez J; Brydges S; Lim WK; Nannuru KC; Murphy AJ; Economides AN; Hatsell SJ; Levi B
Bone; 2020 Sep; 138():115473. PubMed ID: 32553795
[TBL] [Abstract][Full Text] [Related]
37. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
38. Constitutively active ALK2 receptor mutants require type II receptor cooperation.
Bagarova J; Vonner AJ; Armstrong KA; Börgermann J; Lai CS; Deng DY; Beppu H; Alfano I; Filippakopoulos P; Morrell NW; Bullock AN; Knaus P; Mishina Y; Yu PB
Mol Cell Biol; 2013 Jun; 33(12):2413-24. PubMed ID: 23572558
[TBL] [Abstract][Full Text] [Related]
39. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
[TBL] [Abstract][Full Text] [Related]
40. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]